DelMarPharma, a Canada-US biopharma, was approved to start a China Phase II trial of its lead candidate, VAL-083, which targets glioblastomamultiforme (GBM). The trial will test VAL-083 as a first-line GBM treatment in patients with newly diagnosed MGMT-unmethylated disease. Because the trial uses a patient’s MGMT status as a biomarker, it required approval from China’s Human Genetic Resources Administration. DelMar is partnering new China indications for VAL-083 with Guangxi WuzhouPharma, which already markets the drug in China for leukemia and lung cancer.
Source: ChinaBio Today
